Search ARM

Advancing Innovation During COVID-19


ARM Global Regenerative Medicine Sector Report: H1 2020

Despite the unprecedented global challenge presented by COVID-19, the regenerative medicine and advanced therapy sector demonstrated remarkable resilience in the first half of 2020. Patients continued to benefit from the cell and gene therapies currently on the market and in trials, and investment in the sector was robust. Policymakers and regulators recognize the need to continue to promote development for durable and potentially curative therapies for patients with unmet medical needs outside of COVID-19, though challenges remain. The H1 report provides an overview of the current financial, clinical, and policy landscape for these innovative treatments, with commentary from leading experts on the sector.


ARM Global Regenerative Medicine Sector Report: H1 2020

Despite the unprecedented global challenge presented by COVID-19, the regenerative medicine and advanced therapy sector demonstrated remarkable resilience in the first half of 2020. Patients continued to benefit from the cell and gene therapies currently on the market and in trials, and investment in the sector was robust. Policymakers and regulators recognize the need to continue to promote development for durable and potentially curative therapies for patients with unmet medical needs outside of COVID-19, though challenges remain. The H1 report provides an overview of the current financial, clinical, and policy landscape for these innovative treatments, with commentary from leading experts on the sector.

European Sector Landscape

238+

Regenerative Medicine / Advanced Therapies
Companies based in Europe/Israel

2020 European/Israeli Financings

Total EUROPEAN/ISRAELI FINANCING

$2.6 Billion

Approximately €2.3 Billion

103% YoY from H1 2019

Gene & Gene-modified

$2.3 Billion

Approximately €2.0 Billion

111% YoY from H1 2019

Cell
Therapy

$1.8 Billion

Approximately €1.5 Billion

196% YoY from H1 2019

Tissue
Engineering

$29 Million

Approximately €25 Million

 17% YoY from H1 2019

270

Clinical Trials
Sponsored by a European or Israeli developer as of H1 2020